The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening

被引:132
作者
Salit, Irving E. [1 ,2 ]
Lytwyn, Alice [3 ,4 ]
Raboud, Janet [1 ,2 ]
Sano, Marie [1 ]
Chong, Sylvia [4 ]
Diong, Christina [1 ]
Chapman, William [5 ]
Mahony, James B. [4 ,6 ]
Tinmouth, Jill [1 ,2 ,7 ]
机构
[1] Univ Hlth Network, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Henderson Hosp, Hamilton, New Zealand
[4] McMaster Univ, Hamilton, ON L8S 4L8, Canada
[5] St Josephs Hosp, Toronto, ON, Canada
[6] St Josephs Healthcare, Hamilton, New Zealand
[7] Sunnybrook Med Ctr, Toronto, ON M4N 3M5, Canada
关键词
anal cancer; anoscopy; cancer screening; HIV; human papillomavirus; SQUAMOUS INTRAEPITHELIAL LESIONS; ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED PATIENTS; CERVICAL-CANCER; CELL CARCINOMA; POSITIVE MEN; NEOPLASIA; RISK; AIDS; ANUS;
D O I
10.1097/QAD.0b013e328339e592
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To assess anal oncogenic human papillomavirus (HPV) and anal cytology as screening tests for detecting high-grade anal intraepithelial neoplasia (AIN 2+), as this is an immediate anal cancer precursor. Design: Cross-sectional study of 401 HIV-positive men who have sex with men (MSM). The endpoint was histologically confirmed AIN 2+ obtained by high-resolution anoscopy. Cytology and biopsy specimens were assigned random numbers and independently assessed by two pathologists. Methods: We did concomitant anal cytology, anal HPV testing and HRA with directed biopsies without knowing the results of each intervention. The main outcome measures were the sensitivity, specificity, negative predictive value and positive predictive value of anal cytology and oncogenic HPV for the detection of AIN 2+. Results: Cytology was abnormal in 67% of patients: high-grade squamous intraepithelial lesion, 12%; low-grade squamous intraepithelial lesion, 43% and atypical squamous cells of undetermined significance, 12%. Biopsies were abnormal in 68% of patients: AIN 2+, 25% and AIN 1, 43%. HPV was detected in 93% with multiple HPV types in 92% and oncogenic HPV types in 88%. Test performance characteristics for the detection of AIN 2+ using any abnormality on anal cytology were: sensitivity 84%, specificity 39%, negative predictive value 88% and positive predictive value 31%; using oncogenic HPV: sensitivity 100%, specificity 16%, negative predictive value 100% and positive predictive value 28%. Conclusion: Anal cytology and HPV detection have high sensitivity but low specificity for detecting AIN 2+. HIV-positive men who have sex with men have a high prevalence of AIN 2+ and require high-resolution anoscopy for optimal detection of high-grade anal dysplasia. (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
引用
收藏
页码:1307 / 1313
页数:7
相关论文
共 50 条
[41]   Comparison of the performance of anal cytology and cervical cytology as screening tests [J].
Roberts, Jennifer Margaret ;
Thurloe, Julia Kathleen .
SEXUAL HEALTH, 2012, 9 (06) :568-573
[42]   The role of human papillomavirus testing in cervical screening [J].
Cuschieri, KS ;
Cubie, HA .
JOURNAL OF CLINICAL VIROLOGY, 2005, 32 :S34-S42
[43]   Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer [J].
Wang, Chia-ching J. ;
Sparano, Joseph ;
Palefsky, Joel M. .
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 26 (01) :17-+
[44]   Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination [J].
Chen, Meng-Kan ;
Hung, Hui-Fang ;
Duffy, Stephen ;
Yen, Amy Ming-Fang ;
Chen, Hsiu-Hsi .
JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2011, 17 (06) :1050-1058
[45]   Anal Cancer Precursor Lesions in HIV-Infected Persons: Tissue Human Papillomavirus Type Distribution and Impact on Treatment Response [J].
Kobayashi, Takaaki ;
Sigel, Keith ;
Kalir, Tamara ;
MacLeod, Iain J. ;
Liu, Yuxin ;
Gaisa, Michael .
DISEASES OF THE COLON & RECTUM, 2019, 62 (05) :579-585
[46]   Cervical cancer incidence in British Columbia: Predicting effects of changes from Pap to human papillomavirus screening and of changes in screening participation [J].
Coldman, Andrew ;
van Niekerk, Dirk ;
Smith, Laurie ;
Ogilvie, Gina .
JOURNAL OF MEDICAL SCREENING, 2017, 24 (04) :195-200
[47]   Testing for Human Papillomavirus in Cervical Cancer Screening [J].
Ha Thanh Nishino ;
Tambouret, Rosemary H. ;
Wilbur, David C. .
CANCER CYTOPATHOLOGY, 2011, 119 (04) :219-227
[48]   Knowledge of cervical cancer, pap testing and the human papillomavirus among young Australian women [J].
Shand, Lyndel ;
Burney, Sue ;
Fletcher, Jane .
HEALTH PROMOTION JOURNAL OF AUSTRALIA, 2010, 21 (03) :202-207
[49]   Cervical cancer prevention: Human papillomavirus testing as primary screening [J].
Desai, Shreya ;
Zhu, Michelle J. ;
Lapidos-Salaiz, Ilana .
CANCER, 2022, 128 (05) :939-943
[50]   Utility of Human Papillomavirus Testing for Cervical Cancer Screening in Korea [J].
Kim, Mee-seon ;
Lee, Eun Hee ;
Park, Moon-il ;
Lee, Jae Seok ;
Kim, Kisu ;
Roh, Mee Sook ;
Lee, Hyoun Wook .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (05)